Daiichi Sankyo
Naoto Yoshizuka currently serves as Senior Director of Global Translational Development in Oncology R&D at Daiichi Sankyo, Inc., a position held since September 2020. Prior experience includes significant roles at AstraZeneca, where Naoto held titles such as Medical Science Director, Project Leader, and Clinical Science Director focused on Immuno-Oncology within the Oncology TA division. Additionally, Naoto worked as a Medical Advisor at Eli Lilly and Company, contributing to both oncology products and early phase development. Earlier career foundations were established at The Scripps Research Institute as a Research Associate and at the National Institutes of Health as a Visiting Fellow, concentrating on genomics and cell signaling in cancer and HIV/AIDS research. Naoto holds an MD in Medicine from Kanazawa University, earned between 1990 and 1996.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.